Aspen Neuroscience has filed registration documents to go public on Nasdaq under the ticker ASPE, the company disclosed on October 9. Founded in 2018, Aspen is developing a treatment for Parkinson’s disease that takes a patient’s own skin cells, reprograms them into induced pluripotent stem cells, guides them into precursors of dopamine-producing neurons, and surgically implants them. Its lead therapy, sasineprocel, also called ANPD001, has completed early-stage testing and is entering late-stage development.
The manufacturing is the story as much as the biology. The process takes roughly four months per patient, from skin sample to frozen, quality-selected cell batches shipped back to treatment centers for implantation. That model has produced powerful results in some cancers and early signals in autoimmune disease, but it is complex and expensive to run at scale, and no company built specifically around a Parkinson’s cell therapy has listed in the United States before.
The filing is candid about the finances. Aspen recorded a net loss of 62 million dollars in 2025 and almost 37 million dollars in the first six months of 2026, with research and development accounting for more than 70 percent of operating expenses. It has raised approximately 347 million dollars since inception. In the registration documents the company concluded that its existing cash, cash equivalents and marketable securities will not fund operations for another year, that substantial doubt exists about its ability to continue as a going concern, and that even a successful offering will leave it needing substantial additional capital.
The timing is not accidental. Two dozen biotechs have gone public so far in 2026, a pace not seen since 2021, and 16 of them raised at least 250 million dollars. Aspen joins a queue that includes Bambusa Therapeutics and Lycia Therapeutics, which filed this month, while City Therapeutics and Iambic Therapeutics price this week. Whether investors fund a going-concern cell therapy at a full price will say as much about the IPO window as about Aspen.